VEGFR-3 is expressed on megakaryocyte precursors in the murine bone marrow and plays a regulatory role in megakaryopoiesis

Blood

Volumn 120, Issue 9, 2012, Pages 1899-1907

  Thiele, Wilko ^a,b   Krishnan, Jaya ^b   Rothley, Melanie ^a,b   Weih, Debra ^c   Plaumann, Diana ^b   Kuch, Vanessa ^a   Quagliata, Luca ^a   Weich, Herbert A ^d   Sleeman, Jonathan P ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^c FRITZ LIPMANN INSTITUTE   (Germany)

^d HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; THROMBOPOIETIN; VASCULOTROPIN RECEPTOR 3;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ERYTHROLEUKEMIA CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MEGAKARYOBLAST; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MOUSE; NONHUMAN; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEADY STATE; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS; THROMBOCYTOSIS; UPREGULATION;

EID: 84865796608     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-09-376657     Document Type: Article

References (47)

1. Tammela T, Alitalo K. Lymphangiogenesis: Molecular mechanisms and future promise. Cell. 2010;140(4):460-476.
2. Hamada K, Oike Y, Takakura N, et al. VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis. Blood. 2000;96(12):3793-3800.
3. Fernandez Pujol B, Lucibello FC, Zuzarte M, Lutjens P, Muller R, Havemann K. Dendritic cells derived from peripheral monocytes express endothelial markers and in the presence of angiogenic growth factors differentiate into endotheliallike cells. Eur J Cell Biol. 2001;80(1):99-110.
4. Schoppmann SF, Birner P, Stockl J, et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol. 2002;161(3):947-956.
5. Salven P, Mustjoki S, Alitalo R, Alitalo K, Rafii S. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood. 2003;101(1):168-172.
6. Kivivuori SM, Siitonen S, Porkka K, Vettenranta K, Alitalo R, Saarinen-Pihkala U. Expression of vascular endothelial growth factor receptor 3 and Tie1 tyrosine kinase receptor on acute leukemia cells. Pediatr Blood Cancer. 2007;48(4):387-392.
7. Pajusola K, Aprelikova O, Korhonen J, et al. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res. 1992;52(20):5738-5743.
8. Fielder W, Graeven U, Ergün S, et al. Expression of FLT4 and its ligand VEGF-C in acute myeloid leukemia. Leukemia. 1997;11(8):1234-1237.
9. Dias S, Choy M, Alitalo K, Rafii S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood. 2002;99(6):2179-2184.
10. Holmes C, Stanford WL. Concise review: stem cell antigen-1: expression, function, and enigma. Stem Cells. 2007;25(6):1339-1347.
11. Briddell RA, Brandt JE, Straneva JE, Srour EF, Hoffman R. Characterization of the human burst-forming unit-megakaryocyte. Blood. 1989;74(1):145-151.
12. Debili N, Issaad C, Massé JM, et al. Expression of CD34 and platelet glycoproteins during human megakaryocytic differentiation. Blood. 1992;80(12):3022-3035.
13. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005;115(12):3339-3347.
14. Debili N, Coulombel L, Croisille L, et al. Characterization of a bipotent erythro-megakaryocytic progenitor in human bone marrow. Blood. 1996;88(4):1284-1296.
15. Debili N, Louache F, Vainchenker W. Isolation and culture of megakaryocyte precursors. Methods Mol Biol. 2004;272:293-308.
16. Junt T, Schulze H, Chen Z, et al. Dynamic visualization of thrombopoiesis within bone marrow. Science. 2007;317(5845):1767-1770.
17. Rabellino EM, Levene RB, Leung LL, Nachman RL. Human megakaryocytes. II. Expression of platelet proteins in early marrow megakaryocytes. J Exp Med. 1981;154(1):88-100.
18. Levene RB, Lamaziere JM, Broxmeyer HE, Lu L, Rabellino EM. Human megakaryocytes. V. Changes in the phenotypic profile of differentiating megakaryocytes. J Exp Med. 1985;161(3):457-474.
19. Mathur A, Hong Y, Wang G, Erusalimsky JD. Assays of megakaryocyte development: surface antigen expression, ploidy, and size. Methods Mol Biol. 2004;272:309-322.
20. Kirkin V, Mazitschek R, Krishnan J, et al. Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2. Eur J Biochem. 2001;268(21):5530-5540.
21. Casella I, Feccia T, Chelucci C, et al. Autocrineparacrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. Blood. 2003;101(4):1316-1323.
22. Montesano R, Orci L. Tumor-promoting phorbol esters induce angiogenesis in vitro. Cell. 1985;42(2):469-477.
23. Murate T, Saga S, Hotta T, et al. The close relationship between DNA replication and the selection of differentiation lineages of human erythroleukemia cell lines K562, HEL, and TF1 into either erythroid or megakaryocytic lineages. Exp Cell Res. 1993;208(1):35-43.
24. Long MW, Heffner CH, Williams JL, Peters C, Prochownik EV. Regulation of megakaryocyte phenotype in human erythroleukemia cells. J Clin Invest. 1990;85(4):1072-1084.
25. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature. 2000;404(6774):193- 197.
26. Nakorn TN, Miyamoto T, Weissman IL. Characterization of mouse clonogenic megakaryocyte progenitors. Proc Natl Acad Sci U S A. 2003;100(1):205-210.
27. Trevisan M, Iscove NN. Phenotypic analysis of murine long-term hemopoietic reconstituting cells quantitated competitively in vivo and comparison with more advanced colony-forming progeny. J Exp Med. 1995;181(1):93-103.
28. Debili N, Robin C, Schiavon V, et al. Different expression of CD41 on human lymphoid and myeloid progenitors from adults and neonates. Blood. 2001;97(7):2023-2030.
29. Luoh SM, Stefanich E, Solar G, et al. Role of the distal half of the c-Mpl intracellular domain in control of platelet production by thrombopoietin in vivo. Mol Cell Biol. 2000;20(2):507-515.
30. Levin J, Cocault L, Demerens C, et al. Thrombocytopenic c-mpl(-/-) mice can produce a normal level of platelets after administration of 5-fluorouracil: the effect of age on the response. Blood. 2001;98(4):1019-1027.
31. Maruyama K, Ii M, Cursiefen C, et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest. 2005;115(9):2363-2372.
32. Han ZC, Caen JP. Are megakaryocytes and endothelial cells sisters? J Lab Clin Med. 1993;121(6):821-825.
33. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med. 2003;9(6):702-712.
34. Bailey AS, Fleming WH. Converging roads: evidence for an adult hemangioblast. Exp Hematol. 2003;31(11):987-993.
35. Sakamaki S, Hirayama Y, Matsunaga T, et al. Transforming growth factor-beta1 (TGF-beta1) induces thrombopoietin from bone marrow stromal cells, which stimulates the expression of TGF-beta receptor on megakaryocytes and, in turn, renders them susceptible to suppression by TGF-beta itself with high specificity. Blood. 1999;94(6):1961-1970.
36. Shim MH, Hoover A, Blake N, Drachman JG, Reems JA. Gene expression profile of primary human CD34+CD38lo cells differentiating along the megakaryocyte lineage. Exp Hematol. 2004;32(7):638-648.
37. Wartiovaara U, Salven P, Mikkola H, et al. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost. 1998;80(1):171-175.
38. Shinriki S, Jono H, Ueda M, et al. Interleukin-6 signalling regulates vascular endothelial growth factor-C synthesis and lymphangiogenesis in human oral squamous cell carcinoma. J Pathol. 2011;225(1):142-150.
39. Stoffel R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood. 1996;87(2):567-573.
40. Dancea HC, Shareef MM, Ahmed MM. Role of Radiation-induced TGF-beta Signaling in Cancer Therapy. Mol Cell Pharmacol. 2009;1(1):44-56.
41. Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. Science. 1994;265(5177):1445-1447.
42. Thiele W, Sleeman JP. Tumor-induced lymphangiogenesis: a target for cancer therapy? J Biotechnol. 2006;124(1):224-241.
43. Sleeman JP, Thiele W. Tumor metastasis and the lymphatic vasculature. Int J Cancer. 2009;125(12):2747-2756.
44. Heits F, Katschinski DM, Wilmsen U, Wiedemann GJ, JelkmannW. Serum thrombopoietin and interleukin 6 concentrations in tumour patients and response to chemotherapy-induced thrombocytopenia. Eur J Haematol. 1997;59(1):53-58.
45. Sleeman J, Schmid A, Thiele W. Tumor lymphatics. Semin Cancer Biol. 2009;19(5):285-297.
46. Pytowski B, Goldman J, Persaud K, et al. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst. 2005;97(1):14-21.
47. Goldman J, Conley KA, Raehl A, et al. Regulation of lymphatic capillary regeneration by interstitial flow in skin. Am J Physiol Heart Circ Physiol. 2007;292(5):H2176-H2183.